StreetInsider.com News Articles

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Thu, 08 Oct 2026 07:01:00 -0400

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denver, CO.

Details of the oral presentation:

Type of presentation: Late-breaking oral presentation
Abstract title: Durable pgRNA loss in both HBeAg positive and negative

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Thu, 08 Oct 2026 07:01:00 -0400

Details of the oral presentation:

Type of presentation: Late-breaking oral presentation
Abstract title: Durable pgRNA loss in both HBeAg positive and negative

Form 4 PRECISION BIOSCIENCES For: Sep 28 Filed by: Frankel Stanley

Wed, 30 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260930/27128844.html

Form 4 PRECISION BIOSCIENCES For: Sep 25 Filed by: Brown Melinda

Tue, 29 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27117193.html

Form 4 PRECISION BIOSCIENCES For: Sep 25 Filed by: Germano Geno J

Tue, 29 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27117192.html

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

Thu, 27 Aug 2026 08:00:00 -0400

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing
Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed
Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration
Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control

PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced encouraging updated clinical data from the ongoing OTC-HOPE clinical trial evaluating

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

Thu, 27 Aug 2026 08:00:00 -0400

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing
Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed
Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration
Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

Thu, 27 Aug 2026 08:00:00 -0400

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing
Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed
Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration
Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

Thu, 27 Aug 2026 08:00:00 -0400

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing
Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed
Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration
Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control

Form SCHEDULE 13G/A PRECISION BIOSCIENCES Filed by: Weinstein Benjamin

Mon, 24 Aug 2026 15:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26967631.html

Form SCHEDULE 13G/A PRECISION BIOSCIENCES Filed by: Weinstein Benjamin

Mon, 24 Aug 2026 15:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26967631.html

Form 8-K PRECISION BIOSCIENCES For: Aug 24

Mon, 24 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964074.html

Form 8-K PRECISION BIOSCIENCES For: Aug 24

Mon, 24 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964074.html

Precision BioSciences doses first patient in DMD gene-editing trial

Mon, 24 Aug 2026 06:01:19 -0400

Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD as a treatment for Duchenne muscular dystrophy (DMD).

The first patient was dosed at Arkansas Children's Hospital, a Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Care Center and designated Muscular Dystrophy Association Care Center. The company said it expects to report initial safety data by year-end 2026.

PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45-55 of the dystrophin gene, with the aim of restoring a near full-length functional dystrophin protein. According to

Precision BioSciences doses first patient in DMD gene-editing trial

Mon, 24 Aug 2026 06:01:19 -0400

Precision BioSciences doses first patient in DMD gene-editing trial

Mon, 24 Aug 2026 06:01:19 -0400

Precision BioSciences doses first patient in DMD gene-editing trial

Mon, 24 Aug 2026 06:01:19 -0400

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study